Efficacy and safety of weekly carfilzomib (70 mg/m²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

Xavier Leleua Service d'Hématologie et Thérapie cellulaire, CHU and Inserm, Poitiers, FranceCorrespondence[email protected]

https://orcid.org/0000-0002-9822-4170

Meral Beksacb Department of Hematology, Ankara University, Ankara, Turkey

Takaaki Chouc Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan

Meletios Dimopoulosd Hematology and Medical Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece

https://orcid.org/0000-0001-8990-3254

Sung-Soo Yoone Department of Internal Medicine, Seoul National University, Seoul, South Korea

H. Miles Princef Epworth Healthcare and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

Ludek Pourg Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic

Tatiana Shelekhovah Clinic of Professional Pathology, Saratov, Russian Federation

Ajai Charii Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

https://orcid.org/0000-0002-0405-7480

Monica Khuranaj Clinical Development, Oncology, Amgen Inc., Thousand Oaks, CA, USA

Jianqi Zhangk Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA

Mihaela Obrejak Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA, USA

Ming Qil Hematology and Oncology, Janssen Research and Development, LLC, Spring House, PA, USA

Albert Oriolm Institut Català d'Oncologia and Josep Carreras Research Leukaemia Institute, Hospital Germans Trias i Pujol, Barcelona, Spain

David Siegeln John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA

show all

Efficacy and safety of weekly carfilzomib (70 mg/m²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

GLAL-2020-1052-File007.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies

GLAL-2020-1052-File007.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Efficacy and safety of weekly carfilzomib (70 mg/m²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies